Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 1;24(4):195-202.
doi: 10.1097/ACI.0000000000001001. Epub 2024 May 28.

Mast cell conditions and drug allergy: when to suspect and how to manage

Affiliations
Review

Mast cell conditions and drug allergy: when to suspect and how to manage

Bianca Olivieri et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: Patients with mast cell disorders frequently experience symptoms from excessive mediator release like histamine and tryptase, ranging from mild flushing to severe anaphylactic responses. Hypersensitivity reactions (HRs) to drugs are a major cause of anaphylaxis in these patients, who often worry about triggering mast cell degranulation when taking medications. The aim of this review is to explore the complex interactions between mast cell disorders and drug HRs, focusing on the clinical challenges of managing these conditions effectively to enhance understanding and guide safer clinical practices.

Recent findings: Among the drugs most commonly associated with hypersensitivity reactions in patients with mast cell disorders are non-steroidal anti-inflammatory drugs, antibiotics, and perioperative agents. Recent studies have highlighted the role of Mas-related G-protein coupled receptor member X2 (MRGPRX2) - a receptor involved in non-immunoglobulin E mediated mast cell degranulation - in exacerbating HRs. Investigations reveal varied drug tolerance among patients, underscoring the need for individual risk assessments.

Summary: Tailored diagnostic approaches are crucial for confirming drug allergies and assessing tolerance in patients with mastocytosis, preventing unnecessary medication avoidance and ensuring safety before acute situations arise.

PubMed Disclaimer

References

    1. Valent P, Hartmann K, Bonadonna P, et al. Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium. J allergy Clin Immunol Pract 2022; 10:1941–1950.
    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36:1703–1719.
    1. Giannetti MP, Nicoloro-SantaBarbara J, Godwin G, et al. Drug and venom allergy in mastocytosis. Immunol Allergy Clin North Am 2023; 43:699–710.
    1. Giannetti MP, Nicoloro-SantaBarbara J, Godwin G, et al. Challenges in drug and hymenoptera venom hypersensitivity diagnosis and management in mastocytosis. Diagnostics 2024; 14:1–13.
    1. Niedoszytko M, Gorska A, Brockow K, et al. Prevalence of hypersensitivity reactions in various forms of mastocytosis: a pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry. Allergy 2024; doi:10.1111/all.16132. [Online ahead of print]. - DOI

MeSH terms

Substances